193 related articles for article (PubMed ID: 23665979)
1. Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity.
Mori R; Yuzawa M; Akaza E; Haruyama M
Jpn J Ophthalmol; 2013 Jul; 57(4):365-71. PubMed ID: 23665979
[TBL] [Abstract][Full Text] [Related]
2. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity.
Mori R; Tanaka K; Yuzawa M
Medicine (Baltimore); 2018 Jun; 97(25):e11188. PubMed ID: 29924037
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal injection of ranibizumab for recovery of macular function in eyes with subfoveal polypoidal choroidal vasculopathy.
Ogino K; Tsujikawa A; Yamashiro K; Ooto S; Oishi A; Nakata I; Miyake M; Yoshimura N
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3771-9. PubMed ID: 23661367
[TBL] [Abstract][Full Text] [Related]
4. Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Kim CG; Kim JW
Korean J Ophthalmol; 2012 Jun; 26(3):157-62. PubMed ID: 22670070
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.
Matsumiya W; Honda S; Kusuhara S; Tsukahara Y; Negi A
BMC Ophthalmol; 2013 Apr; 13():10. PubMed ID: 23557322
[TBL] [Abstract][Full Text] [Related]
6. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
[TBL] [Abstract][Full Text] [Related]
7. Two-year results of intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.
Saito M; Iida T; Kano M; Itagaki K
Eye (Lond); 2013 Aug; 27(8):931-9. PubMed ID: 23743532
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Cho HJ; Kim JW; Lee DW; Cho SW; Kim CG
Eye (Lond); 2012 Mar; 26(3):426-33. PubMed ID: 22173075
[TBL] [Abstract][Full Text] [Related]
10. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Yoshida Y; Kohno T; Yamamoto M; Yoneda T; Iwami H; Shiraki K
Jpn J Ophthalmol; 2013 May; 57(3):283-93. PubMed ID: 23413039
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
[TBL] [Abstract][Full Text] [Related]
12. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.
Hikichi T; Higuchi M; Matsushita T; Kosaka S; Matsushita R; Takami K; Ohtsuka H; Ariga H
Am J Ophthalmol; 2012 Jul; 154(1):117-124.e1. PubMed ID: 22465366
[TBL] [Abstract][Full Text] [Related]
13. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Song MH; Ryu HW; Roh YJ
Ophthalmologica; 2011; 226(3):119-26. PubMed ID: 21757883
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
15. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
16. Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Kang EC; Choi S; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2157-2163. PubMed ID: 28819823
[TBL] [Abstract][Full Text] [Related]
17. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1272-9. PubMed ID: 22547209
[TBL] [Abstract][Full Text] [Related]
18. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Oct; 156(4):652-60. PubMed ID: 23891333
[TBL] [Abstract][Full Text] [Related]
19. Polypoidal choroidal vasculopathy exudation and hemorrhage: results of monthly ranibizumab therapy at one year.
Kokame GT; Yeung L; Teramoto K; Lai JC; Wee R
Ophthalmologica; 2014; 231(2):94-102. PubMed ID: 24135557
[TBL] [Abstract][Full Text] [Related]
20. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months.
Hikichi T; Ohtsuka H; Higuchi M; Matsushita T; Ariga H; Kosaka S; Matsushita R; Takami K
Am J Ophthalmol; 2010 Nov; 150(5):674-682.e1. PubMed ID: 20691424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
